TY - JOUR T1 - Spironolactone reduced mortality in severe congestive heart failure JF - Evidence Based Medicine JO - Evid Based Med SP - 11 LP - 11 DO - 10.1136/ebm.5.1.11 VL - 5 IS - 1 A2 - , Y1 - 2000/01/01 UR - http://ebm.bmj.com/content/5/1/11.abstract N2 - (1999) N Engl J Med 341, 709. Pitt B, Zannad F, Remme WJ, et al. for the Randomized Aldactone Evaluation Study Investigators. . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. . . Sep 2;. :. –17.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In patients with severe congestive heart failure (CHF) caused by systolic left ventricular dysfunction, does spironolactone combined with usual care reduce all-cause mortality? Randomised (allocation concealed*), blinded (patients, clinicians, and outcome assessors),* placebo-controlled trial with mean follow-up of 24 months. Interim analyses were done. 195 clinical centres in 15 countries. 1663 patients (mean age 65 y, 73% men, 87% white) with severe CHF who were using angiotensin-converting enzyme (ACE) inhibitors, if tolerated, and a loop diuretic and had had a recent left ventricular ejection fraction ≤35%. The major exclusion criterion was use of potassium-sparing diuretics. All patients were analysed. All patients received usual care and were allocated to spironolactone, 25 mg/day, which could be doubled after 8 weeks … ER -